While Kevin Nalty worked during the day as Con-sumer Product Director at Merck, where he marketed Propecia, at night and on weekends he was making comedic videos for YouTube -- a few of which were critical of drug ads, marketing, and medical conditions. Read this interesting story and learn how not to get fired doing new media marketing.
Arnold Friede, counsel to the law firm McDermott Will & Emery LLP, and former Senior Counsel at Pfizer, believes that there is an opportunity now to make a strong and compelling argument for the adoption of rational regulatory policies by the FDA that address the unique features not only of sponsored links, but of other kinds of new communication tools, such as social media.
This article presents a summary of a recent TNS Healthcare webinar and personal conversations with presenters conducted beforehand. Included are NEW research results about how US and European physicians rate pharmaceutical companies against a number of customer value points that are important in achieving success with the new sales model.
Welcome to the May 2009 issue of Pharma Marketing News.
In this guest article, Carla Stratfold, CEO at OnRequest Images, presents several key learnings and best practices that pharmas can follow when building brand and consumer loyalty.
Welcome to the September 2009 issue of Pharma Marketing News.
Welcome to the August 2009 issue of Pharma Marketing News.
In response to concerns about the growing range of threats to brand value and the sheer volume of brand hijacking incidents, the CMO Council set out to assess the challenges marketers face as stewards of their brands. The result is Protection from Brand Infection, a seminal authority leadership report that outlines the proliferating threat-scape that marketers face and reveals how marketers are struggling to understand and measure the impact brand intrusions have on their second most valuable asset, their customer.
Welcome to the March 2009 issue of Pharma Marketing News.
The recent FDA Draft Guidance for Industry, Presenting Risk Information in Prescription Drug and Medical Device Promotion guidance focuses almost exclusively on print and broadcast promotional ads. It is possible, however, to apply some of FDA's